Medicinal Plants as Sources of Immunomodulatory Drugs: Bioactive Phytochemicals, Mechanistic Insights, and Translational Opportunities for Immune-Targeted Therapy

Takumi Hiroshi Fujimoto [1*], Aiko Misaki Yamamoto [2], Ryoichi Kenji Tanaka [3], Haruka Emi Nakamura [4], Daichi Ren Saito [5]

[1]PhD, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Japan
[2] PhD, Center for Advanced Drug Delivery Systems, Kyoto University, Japan
[3] PhD, Institute for Precision Oncology Nanotechnology, Osaka University, Japan
[4] PhD, Department of Nanopharmaceutical Engineering, Hokkaido University, Japan
[5] PhD, Laboratory of Targeted Nanotherapeutics, Nagoya University, Japan

* Corresponding Author: **Takumi Hiroshi Fujimoto**

Article Info

ISSN (online): 3107-393X
Volume: 01
Issue: 02
March – April 2024
Received: 05-01-2024
Accepted: 07-02-2024
Published: 09-03-2024
Page No: 30-43

Abstract
The modulation of immune function represents a critical therapeutic strategy for managing autoimmune disorders, chronic inflammation, immunodeficiency states, and cancer. While synthetic immunomodulatory agents have demonstrated clinical efficacy, concerns regarding adverse effects, high costs, and limited accessibility have prompted renewed interest in plant-derived alternatives. This review examines the immunomodulatory potential of medicinal plants, focusing on bioactive phytochemicals, underlying molecular mechanisms, and translational opportunities for drug development. Numerous traditional medicinal plants, including Echinacea purpurea, Withania somnifera, Panax ginseng, Curcuma longa, and Astragalus membranaceus, have demonstrated capacity to modulate both innate and adaptive immune responses through diverse mechanisms. Key phytochemicals such as polysaccharides, alkaloids, terpenoids, flavonoids, and phenolic compounds influence cytokine production, regulate lymphocyte proliferation, enhance natural killer cell activity, and modulate pattern recognition receptor signaling. Preclinical studies in cellular and animal models have consistently demonstrated immunostimulatory or immunosuppressive effects depending on dosage, extraction method, and disease context. Clinical investigations, though limited in number and methodological rigor, suggest therapeutic potential in respiratory infections, inflammatory conditions, and adjuvant cancer therapy. However, challenges including phytochemical standardization, formulation optimization, pharmacokinetic limitations, herb-drug interactions, and regulatory compliance must be addressed. This review synthesizes current evidence on plant-derived immunomodulators and identifies critical gaps requiring further investigation to facilitate their rational integration into evidence-based therapeutic regimens and pharmaceutical development pipelines.

DOI:

Keywords: Medicinal plants, Immunomodulatory drugs, Phytochemicals, Immune modulation, Translational research, Cytokines, Drug development

Introduction

The immune system serves as the principal defense mechanism against infectious pathogens, malignant transformation, and tissue damage, while simultaneously maintaining tolerance to self-antigens and commensal microorganisms. Dysregulation of immune homeostasis underlies a diverse spectrum of pathological conditions, including autoimmune diseases, allergic disorders, chronic inflammatory states, immunodeficiency syndromes, and cancer. Consequently, pharmacological modulation of immune function has emerged as a cornerstone of contemporary therapeutic interventions. Current immunomodulatory drugs encompass immunosuppressive agents such as corticosteroids, calcineurin inhibitors, and antimetabolites, as well as immunostimulatory biologics including cytokines, monoclonal antibodies, and checkpoint inhibitors. Despite their clinical utility, these agents are frequently associated with significant adverse effects, including opportunistic infections, metabolic disturbances, organ toxicity, and prohibitive costs that limit accessibility in resource-constrained settings [1, 2].

Traditional medicine systems across diverse cultures have employed plant-based remedies for centuries to enhance resistance to infections, reduce inflammation, and restore physiological balance. Ethnopharmacological investigations have identified numerous medicinal plants with purported immunomodulatory properties, many of which have been subjected to scientific scrutiny in recent decades. The therapeutic potential of plant-derived immunomodulators stems from their complex phytochemical composition, which enables multi-target modulation of immune pathways through mechanisms distinct from those of conventional synthetic drugs. Furthermore, botanical preparations often exhibit favorable safety profiles and reduced costs compared to their pharmaceutical counterparts, rendering them attractive candidates for drug development and complementary therapeutic strategies [3, 4].

The resurgence of interest in natural products as sources of novel therapeutics has been catalyzed by advances in analytical chemistry, molecular immunology, and systems pharmacology, which have facilitated the characterization of bioactive constituents, elucidation of mechanistic pathways, and evaluation of clinical efficacy. High-throughput screening platforms, omics technologies, and in silico modeling have accelerated the identification of immunoactive phytochemicals and their molecular targets. Concurrently, growing recognition of the limitations of reductionist approaches has fostered appreciation for the synergistic interactions among multiple constituents in complex botanical matrices, prompting investigation of standardized extracts and multi-component formulations [5, 6].

This comprehensive review examines the current state of knowledge regarding medicinal plants as sources of immunomodulatory drugs. The objectives are to provide an overview of immune system biology and immunomodulation concepts, survey medicinal plants with documented immunomodulatory activity, elucidate the bioactive compounds and molecular mechanisms underlying their effects, synthesize preclinical and clinical evidence, discuss formulation and delivery strategies, evaluate safety and toxicity concerns, address regulatory and standardization challenges, and identify future directions for translational research and pharmaceutical development. By integrating insights from traditional knowledge systems with contemporary scientific evidence, this review aims to inform rational utilization of plant-derived immunomodulators in clinical practice and guide strategic investment in drug discovery efforts.

Immune System Overview and the Concept of Immunomodulation

The immune system comprises an intricate network of cells, tissues, soluble mediators, and molecular pathways that collectively orchestrate defense against foreign antigens while maintaining self-tolerance. Functionally, immunity is divided into innate and adaptive arms, which operate synergistically through bidirectional communication. The innate immune system provides rapid, non-specific responses mediated by physical barriers, pattern recognition receptors, phagocytic cells, natural killer cells, and soluble factors including complement proteins and antimicrobial peptides. Pattern recognition receptors such as Toll-like receptors, NOD-like receptors, and C-type lectin receptors recognize pathogen-associated molecular patterns and damage-associated molecular patterns, initiating inflammatory cascades and shaping subsequent adaptive responses [7, 8].

Adaptive immunity develops more slowly but confers antigen-specific recognition and immunological memory through the activities of T lymphocytes and B lymphocytes. CD4-positive helper T cells differentiate into distinct subsets, including Th1, Th2, Th17, and regulatory T cells, each characterized by specific cytokine profiles and effector functions. CD8-positive cytotoxic T lymphocytes eliminate infected or malignant cells through targeted cytolysis. B lymphocytes produce antibodies that neutralize pathogens, opsonize antigens for phagocytosis, and activate complement. Antigen-presenting cells, particularly dendritic cells, serve as critical intermediaries between innate and adaptive immunity by processing and presenting antigens to naive T cells in secondary lymphoid organs [9, 10].

Immunomodulation refers to the therapeutic manipulation of immune function to achieve desired clinical outcomes. This encompasses both immunostimulation, which enhances immune responses in contexts of immunodeficiency, infection, or cancer, and immunosuppression, which attenuates excessive or misdirected immune activation in autoimmune diseases, transplantation, and chronic inflammation. Immunomodulatory interventions may target specific cellular populations, cytokine networks, signaling pathways, or effector mechanisms. The concept of immunomodulation has evolved from crude manipulation of immune responses toward precision targeting of discrete molecular pathways, facilitated by advances in understanding immune cell biology and the development of biologics targeting specific receptors or ligands [11, 12].

Effective immunomodulation requires consideration of the bidirectional nature of immune regulation, wherein stimulation of certain pathways may indirectly suppress others through feedback mechanisms and cytokine networks. The balance between pro-inflammatory and anti-inflammatory signals, effector and regulatory cell populations, and activating and inhibitory receptors determines the magnitude and quality of immune responses. Dysregulation of these homeostatic mechanisms contributes to pathology, and restoration of appropriate immune balance represents the ultimate goal of immunomodulatory therapy. Plant-derived immunomodulators often exert pleiotropic effects on multiple immune parameters, potentially offering advantages in conditions requiring restoration of immune homeostasis rather than unidirectional manipulation [13, 14].

The evaluation of immunomodulatory activity requires comprehensive assessment of diverse immune parameters across multiple experimental systems. *In vitro* assays examine effects on isolated immune cells, including lymphocyte proliferation, cytokine production, phagocytic activity, natural killer cell cytotoxicity, and expression of surface markers. *In vivo* models assess systemic immune responses in healthy animals or disease models, evaluating parameters such as antibody production, delayed-type hypersensitivity responses, resistance to infection, tumor growth inhibition, and modulation of inflammatory pathology. Ex vivo analysis of immune cells from treated subjects provides translational insights into mechanisms operative in complex biological systems. Integration of data across these experimental platforms enables comprehensive characterization of immunomodulatory potential and informs rational therapeutic application [15, 16].

Medicinal Plants with Immunomodulatory Activity

Traditional medicine systems worldwide have employed numerous plant species for enhancing resistance to disease, treating infections, and managing inflammatory conditions, many of which demonstrate immunomodulatory properties upon scientific investigation. Echinacea purpurea, widely used in North American and European phytotherapy, has been extensively studied for immunostimulatory effects. Preparations of Echinacea have demonstrated capacity to enhance phagocytic activity of macrophages, stimulate natural killer cell function, increase production of interferon and other cytokines, and augment antibody responses. Clinical applications have focused primarily on prevention and treatment of upper respiratory tract infections, though evidence regarding efficacy remains debated [17, 18].

Withania somnifera, known as ashwagandha in Ayurvedic medicine, possesses adaptogenic and immunomodulatory properties attributed to withanolide compounds. Studies indicate that Withania extracts modulate both innate and adaptive immunity, enhancing cell-mediated immunity while also demonstrating anti-inflammatory effects through suppression of pro-inflammatory cytokines and inhibition of nuclear factor kappa B signaling. Traditional uses encompass general health promotion, stress resilience, and management of inflammatory conditions. Contemporary research has explored applications in cancer immunotherapy, autoimmune diseases, and age-related immune dysfunction [19, 20].

Panax ginseng, a cornerstone of traditional Chinese and Korean medicine, contains ginsenosides as principal bioactive constituents responsible for diverse pharmacological effects including immunomodulation. Ginseng preparations have been shown to enhance macrophage and natural killer cell activity, stimulate cytokine production, promote lymphocyte proliferation, and improve antibody responses. Additionally, certain ginsenosides demonstrate immunosuppressive properties useful in managing excessive inflammation. Clinical investigations have examined ginseng supplementation for improving immune function in elderly individuals, enhancing vaccine responses, and supporting cancer patients undergoing chemotherapy [21, 22].

Curcuma longa, the source of the polyphenolic compound curcumin, has been employed in Ayurvedic and traditional Chinese medicine for treating inflammatory and infectious conditions. Curcumin exhibits potent anti-inflammatory and immunomodulatory effects through multiple mechanisms, including inhibition of pro-inflammatory transcription factors, modulation of T cell differentiation, regulation of cytokine production, and suppression of inflammatory enzyme activity. Despite promising preclinical data, clinical translation has been limited by poor bioavailability, necessitating development of enhanced formulations. Therapeutic applications under investigation include inflammatory bowel disease, arthritis, and cancer [23, 24].

Astragalus membranaceus, widely utilized in traditional Chinese medicine as an immune tonic, contains polysaccharides and saponins as major immunoactive constituents. Astragalus preparations demonstrate immunostimulatory effects including enhancement of macrophage phagocytosis, augmentation of natural killer cell activity, stimulation of interferon production, and promotion of lymphocyte proliferation. Clinical applications have focused on supporting immune function in cancer patients, preventing respiratory infections, and managing chronic fatigue. Contemporary research has explored molecular mechanisms underlying these effects and potential synergies with conventional immunotherapies [25, 26].

Numerous additional medicinal plants have demonstrated immunomodulatory potential in scientific investigations. Uncaria tomentosa, or cat's claw, native to the Amazon rainforest, exhibits anti-inflammatory and immunostimulatory properties attributed to pentacyclic oxindole alkaloids and quinovic acid glycosides. Andrographis paniculata, employed in traditional Asian medicine, contains andrographolides with immunomodulatory and anti-inflammatory effects relevant to respiratory infections and inflammatory conditions. Glycyrrhiza glabra, or licorice, possesses glycyrrhizin and other triterpenoids demonstrating immunomodulatory, anti-inflammatory, and antiviral activities. Tinospora cordifolia, a valued plant in Ayurvedic medicine, contains diverse phytochemicals contributing to immunostimulatory effects and has been investigated for applications in infections, inflammation, and cancer [27, 28, 29, 30].

Table 1: Selected medicinal plants with immunomodulatory effects, active constituents, and traditional uses

Plant Species	Common Name	Major Active Constituents	Traditional Uses	Primary Immunomodulatory Effects
Echinacea purpurea	Purple coneflower	Alkylamides, polysaccharides, caffeic acid derivatives	Prevention and treatment of infections, wound healing	Enhanced phagocytosis, NK cell activation, cytokine stimulation
Withania somnifera	Ashwagandha	Withanolides, withaferins	Adaptogen, anti-inflammatory, general tonic	T cell modulation, anti-inflammatory cytokine regulation
Panax ginseng	Asian ginseng	Ginsenosides, polysaccharides	Energy enhancement, longevity, stress resistance	Macrophage activation, lymphocyte proliferation, cytokine production
Curcuma longa	Turmeric	Curcumin, demethoxycurcumin, bisdemethoxycurcumin	Anti-inflammatory, digestive disorders, wound healing	NF-κB inhibition, T cell regulation, anti-inflammatory effects
Astragalus membranaceus	Astragalus	Polysaccharides, saponins, flavonoids	Immune tonic, fatigue, infections	Enhanced phagocytosis, interferon production, lymphocyte stimulation
Uncaria tomentosa	Cat's claw	Pentacyclic oxindole alkaloids, quinovic acid glycosides	Inflammation, arthritis, infections	Anti-inflammatory, enhanced immune cell function
Andrographis paniculata	King of bitters	Andrographolides, diterpenoid lactones	Respiratory infections, fever, inflammation	Anti-inflammatory, enhanced cellular immunity
Glycyrrhiza glabra	Licorice	Glycyrrhizin, liquiritin, isoliquiritigenin	Digestive disorders, respiratory conditions, inflammation	Anti-inflammatory, antiviral, immune regulation
Tinospora cordifolia	Guduchi	Alkaloids, diterpenoid lactones, polysaccharides	Fever, infections, general tonic	Enhanced phagocytosis, antibody production, cytokine modulation
Allium sativum	Garlic	Organosulfur compounds, allicin	Infections, cardiovascular health, inflammation	Enhanced NK cell and macrophage activity, cytokine modulation

Bioactive Compounds and Mechanisms of Action

The immunomodulatory effects of medicinal plants are attributed to diverse classes of phytochemicals that interact with multiple molecular targets within immune cells and their regulatory pathways. Polysaccharides represent a major category of immunoactive compounds, particularly those derived from plants such as Astragalus, Echinacea, and various medicinal mushrooms. These complex carbohydrates exert immunostimulatory effects primarily through activation of pattern recognition receptors, including Toll-like receptors, complement receptor 3, and Dectin-1. Polysaccharide binding to these receptors initiates intracellular signaling cascades involving mitogen-activated protein kinases, nuclear factor kappa B, and interferon regulatory factors, culminating in enhanced production of pro-inflammatory cytokines, increased phagocytic activity, and augmented cytotoxic function. Structural features including molecular weight, glycosidic linkage patterns, and degree of branching influence immunological activity and receptor specificity [31, 32].

Alkaloids constitute another significant class of bioactive compounds with immunomodulatory properties. The withanolides from Withania somnifera modulate immune function through multiple mechanisms, including regulation of heat shock protein expression, modulation of glucocorticoid receptor signaling, and interference with inflammatory transcription factor activation. Berberine, an isoquinoline alkaloid found in several medicinal plants, demonstrates immunosuppressive effects through inhibition of pro-inflammatory cytokine production, suppression of T cell proliferation, and modulation of macrophage polarization toward anti-inflammatory phenotypes. The indole alkaloids from Uncaria tomentosa exhibit anti-inflammatory properties through inhibition of nuclear factor kappa B activation and suppression of inflammatory mediator synthesis [33, 34].

Terpenoids and saponins represent diverse structural classes with significant immunomodulatory potential. Ginsenosides from Panax species demonstrate complex immunological effects dependent on specific structural variants. Some ginsenosides enhance immune function through stimulation of cytokine production, augmentation of natural killer cell activity, and promotion of dendritic cell maturation, while others exhibit immunosuppressive properties useful in managing inflammatory conditions. Ursolic acid and oleanolic acid, pentacyclic triterpenes widely distributed in medicinal plants, modulate immune responses through regulation of transcription factors, cytokine production, and immune cell migration. The mechanisms involve interference with nuclear factor kappa B and activator protein-1 signaling, as well as modulation of mitogen-activated protein kinase pathways [35, 36].

Flavonoids and phenolic compounds constitute ubiquitous plant metabolites with established anti-inflammatory and immunomodulatory activities. Curcumin, a diferuloylmethane polyphenol, exerts potent anti-inflammatory effects through pleiotropic mechanisms including direct inhibition of nuclear factor kappa B, suppression of cyclooxygenase-2 and inducible nitric oxide synthase expression, modulation of T cell differentiation, and regulation of regulatory T cell function. Quercetin and other flavonols demonstrate immunomodulatory effects through inhibition of inflammatory signaling pathways, modulation of mast cell degranulation, and regulation of immune cell activation. Epigallocatechin gallate from green tea exhibits anti-inflammatory properties through suppression of pro-inflammatory cytokine production and modulation of T cell responses [37, 38].

The molecular mechanisms underlying immunomodulation by plant-derived compounds involve complex interactions with intracellular signaling networks. A central pathway frequently targeted is the nuclear factor kappa B system, which regulates expression of numerous genes involved in inflammation, immune cell activation, and cytokine production. Many phytochemicals inhibit nuclear factor kappa B activation through diverse mechanisms including suppression of inhibitor of kappa B kinase activity, prevention of inhibitor of kappa B degradation, interference with nuclear translocation, or direct interaction with DNA binding. Additional targets include mitogen-activated protein kinase cascades, Janus kinase-signal transducer and activator of transcription pathways, phosphoinositide 3-kinase-Akt signaling, and nuclear factor erythroid 2-related factor 2-mediated antioxidant responses [39, 40].

Modulation of cytokine networks represents a critical mechanism by which plant-derived compounds influence immune responses. Many immunoactive phytochemicals alter the balance between pro-inflammatory cytokines such as tumor necrosis factor alpha, interleukin-1 beta, and interleukin-6, and anti-inflammatory mediators including interleukin-10 and transforming growth factor beta. This modulation occurs at multiple levels including transcriptional regulation, post-transcriptional processing, secretion, and receptor signaling. Some compounds preferentially enhance type 1 cytokine responses characterized by interferon gamma production and cell-mediated immunity, while others promote type 2 responses or regulatory cytokine profiles. The specific effects depend on compound structure, concentration, cellular context, and pre-existing activation state [41, 42].



Fig 1: Mechanistic overview of plant-derived immunomodulators acting on innate and adaptive immune pathways.

Table 2: Molecular targets and immunological pathways modulated by key phytochemicals

Phytochemical Class	Representative Compounds	Primary Molecular Targets	Signaling Pathways Affected	Immunological Outcomes
Polysaccharides	Astragalus polysaccharides, beta-glucans, arabinogalactans	TLR4, TLR2, Dectin-1, CR3	NF-κB, MAPK, IRF activation	Enhanced phagocytosis, cytokine production, NK cell activity
Withanolides	Withaferin A, withanolide D	Hsp90, GR, IKK	NF-κB inhibition, stress response modulation	Anti-inflammatory effects, T cell modulation
Ginsenosides	Rg1, Rb1, Rh2	Cytokine receptors, glucocorticoid receptors	JAK–STAT, MAPK, PI3K–Akt	Enhanced or suppressed cytokine production, lymphocyte modulation
Curcuminoids	Curcumin, demethoxycurcumin	IKK, COX-2, iNOS, STAT3	NF-κB, AP-1, Nrf2 pathways	Anti-inflammatory, regulatory T cell promotion, cytokine regulation
Alkaloids	Berberine, andrographolide	AMPK, NF-κB, MAPK	Metabolic and inflammatory pathway suppression	Immunosuppression, anti-inflammatory effects
Flavonoids	Quercetin, EGCG, baicalein	Kinases, phosphodiesterases, transcription factors	MAPK, NF-κB, PI3K inhibition	Anti-inflammatory, mast cell stabilization, T cell regulation
Triterpenoids	Ursolic acid, oleanolic acid, glycyrrhizin	NF-κB, AP-1, STAT	Transcription factor inhibition	Anti-inflammatory, macrophage polarization
Organosulfur compounds	Allicin, diallyl sulfides	NF-κB, Nrf2, redox systems	Antioxidant and anti-inflammatory pathways	Enhanced innate immunity, anti-inflammatory effects
Quinovic acid glycosides	Quinovic acid derivatives	NF-κB, inflammatory enzymes	Inflammatory cascade inhibition	Anti-inflammatory, immune cell function modulation
Diterpenoid lactones	Andrographolide, tinosporides	NF-κB, AP-1, complement	Multiple anti-inflammatory pathways	Reduced inflammation, enhanced cellular immunity

Preclinical Evidence: *In vitro* and *In vivo* Models

Extensive preclinical investigations employing cellular and animal models have characterized the immunomodulatory properties of medicinal plants and their isolated constituents. *In vitro* studies utilizing isolated immune cells provide mechanistic insights and enable systematic evaluation of concentration-dependent effects. Peripheral blood mononuclear cells, purified lymphocyte populations, macrophage cell lines, and dendritic cells serve as common experimental systems. Echinacea extracts have demonstrated dose-dependent stimulation of macrophage phagocytosis, enhancement of natural killer cell cytotoxicity against tumor targets, and augmentation of T cell proliferation in response to mitogenic stimuli. These effects correlate with increased production of tumor necrosis factor alpha, interleukin-1, interleukin-6, and interferon, suggesting coordinated activation of pro-inflammatory pathways [43, 44].

Withania somnifera extracts and purified withanolides have exhibited complex immunomodulatory effects in cellular systems. Studies demonstrate enhanced proliferation of lymphocytes, increased production of interferon gamma indicative of Th1 polarization, and augmented cytotoxic T lymphocyte activity. Concurrently, withanolides suppress production of pro-inflammatory cytokines in activated macrophages and inhibit nuclear factor kappa B activation, suggesting capacity for bidirectional immune modulation dependent on cellular context and activation state. *In vitro* models of oxidative stress and inflammation indicate that Withania constituents protect immune cells from damage while maintaining functional capacity [45, 46].

Polysaccharide fractions isolated from Astragalus membranaceus have been extensively characterized in cellular immunoassays. These compounds activate macrophages as evidenced by enhanced phagocytic uptake, increased nitric oxide production, elevated expression of major histocompatibility complex class II molecules, and augmented cytokine secretion. Natural killer cells exposed to Astragalus polysaccharides demonstrate increased cytolytic activity against tumor cell targets and enhanced interferon production. Dendritic cells treated with these polysaccharides exhibit maturation characterized by upregulation of costimulatory molecules and improved capacity to stimulate naive T cell responses. Mechanistic studies confirm engagement of Toll-like receptor 4 and downstream signaling through nuclear factor kappa B and mitogen-activated protein kinase pathways [47, 48].

In vivo animal models provide essential information regarding systemic immune effects, dose-response relationships, and therapeutic potential in disease contexts. Immunocompetent rodents treated with ginseng extracts demonstrate enhanced antibody responses to administered antigens, improved delayed-type hypersensitivity reactions, and increased resistance to bacterial and viral infections. These effects correlate with expansion of lymphoid populations, enhanced cytokine production, and augmented natural killer cell activity in spleen and lymph nodes. Aging animal models have revealed that ginseng supplementation partially restores age-related decline in immune function, including improved T cell proliferative capacity and enhanced antibody production [49, 50].

Tumor-bearing animal models have been employed extensively to evaluate immunostimulatory effects of medicinal plants in cancer contexts. Astragalus administration in mice with implanted tumors has demonstrated reduced tumor growth, increased survival, and enhanced cytotoxic T lymphocyte infiltration into tumor tissue. Combination studies indicate that Astragalus potentiates the effects of chemotherapy and checkpoint inhibitor immunotherapy through multiple mechanisms including enhanced dendritic cell function, improved T cell priming, and reversal of tumor-induced immunosuppression. Similar effects have been observed with Echinacea, Uncaria, and other immunostimulatory botanicals [51, 52].

Inflammation and autoimmunity models provide insights into immunosuppressive and anti-inflammatory applications of medicinal plants. Curcumin administration in experimental arthritis models reduces joint inflammation, decreases production of pro-inflammatory cytokines, suppresses T helper 17 cell responses, and promotes regulatory T cell expansion. Inflammatory bowel disease models demonstrate that curcumin attenuates intestinal inflammation through inhibition of nuclear factor kappa B signaling, reduction of inflammatory cell infiltration, and restoration of epithelial barrier function. Glycyrrhizin has shown protective effects in autoimmune disease models through suppression of autoreactive T cell responses and modulation of cytokine networks [53, 54].

Infection models have been utilized to assess immunostimulatory effects relevant to antimicrobial defense. Animals treated with Echinacea or Andrographis extracts prior to experimental infection demonstrate reduced pathogen burden, decreased mortality, and accelerated pathogen clearance compared to untreated controls. These effects associate with enhanced innate immune responses including increased phagocytic activity, elevated interferon production, and improved natural killer cell function. Combination studies with conventional antimicrobials suggest potential for additive or synergistic effects, though optimal dosing and timing require further investigation.

Immunotoxicity and immunosuppression models have evaluated the capacity of medicinal plants to restore immune function following chemical or radiation-induced damage. Astragalus and ginseng administration following cyclophosphamide treatment or irradiation has demonstrated accelerated recovery of lymphocyte populations, restoration of cytokine production, and improved resistance to opportunistic infections. These findings suggest potential applications in supporting immune function during cancer therapy or other immunosuppressive treatments. However, concerns regarding potential interference with therapeutic immunosuppression in transplantation contexts necessitate careful evaluation.

Table 3: Summary of preclinical and clinical evidence, including outcomes and safety observations

Plant Species	Preclinical Models	Key Preclinical Findings	Clinical Studies	Clinical Outcomes	Safety Observations
Echinacea purpurea	*In vitro* immune cells, infection models, tumor models	Enhanced phagocytosis, NK cell activity, cytokine production, reduced infection severity	Prevention and treatment of URTIs, immunostimulation	Modest reduction in URTI duration and severity in some studies, inconsistent results	Generally, well tolerated, rare allergic reactions, concerns in autoimmune diseases
Withania somnifera	*In vitro* lymphocytes, stress models, inflammation models	Enhanced cell-mediated immunity, anti-inflammatory effects, stress adaptation	Cancer adjuvant, stress, inflammation	Improved quality of life in cancer patients, reduced inflammation markers, stress reduction	Well tolerated at standard doses, potential for sedation, thyroid hormone effects
Panax ginseng	*In vitro* immune cells, aging models, infection models	Enhanced macrophage and NK cell activity, improved antibody responses	Immunostimulation in elderly, cancer support, vaccine adjuvant	Enhanced immune parameters, possible improved vaccine responses, variable cancer outcomes	Generally safe, possible insomnia, hypertension at high doses, herb–drug interactions
Curcuma longa	*In vitro* inflammatory cells, arthritis models, colitis models	NF-κB inhibition, reduced inflammation, T cell modulation	Inflammatory conditions, cancer	Reduced inflammation in some studies, limited by bioavailability	Excellent safety profile, GI disturbances at high doses, limited bioavailability
Astragalus membranaceus	*In vitro* immune cells, tumor models, immunosuppression models	Enhanced phagocytosis, interferon production, tumor immunity	Cancer adjuvant, chronic infections, fatigue	Improved immune parameters in cancer, reduced infection frequency	Well tolerated, potential for excessive immunostimulation in autoimmune conditions
Uncaria tomentosa	*In vitro* immune cells, inflammation models	Anti-inflammatory, enhanced immune cell function	Osteoarthritis, inflammation	Reduced pain and inflammation in arthritis	Generally safe, GI effects, potential bleeding risk
Andrographis paniculata	*In vitro* immune cells, infection models	Anti-inflammatory, enhanced cellular immunity	URTIs, inflammation	Reduced URTI symptoms and duration	Well tolerated, allergic reactions rare, potential GI effects
Glycyrrhiza glabra	*In vitro* immune cells, inflammation models, viral infection models	Anti-inflammatory, antiviral, immune modulation	Viral hepatitis, peptic ulcers, inflammation	Antiviral effects, anti-inflammatory benefits	Mineralocorticoid effects with prolonged use, hypertension, hypokalemia
Tinospora cordifolia	*In vitro* immune cells, infection models, inflammation models	Enhanced phagocytosis, cytokine modulation	Allergic rhinitis, infections	Reduced allergic symptoms, possible immunostimulation	Generally safe, potential blood glucose effects
Allium sativum	*In vitro* immune cells, infection models, tumor models	Enhanced NK and macrophage activity, cytokine modulation	Cardiovascular health, immunostimulation	Modest cardiovascular benefits, inconsistent immune effects	Generally safe, GI effects, odor, bleeding risk at high doses

Clinical Evidence and Therapeutic Applications

Clinical investigations of plant-derived immunomodulators have expanded considerably in recent decades, though methodological limitations and heterogeneity of study designs complicate definitive conclusions regarding efficacy.

Echinacea represents one of the most extensively studied botanical immunomodulators in clinical trials, primarily for prevention and treatment of upper respiratory tract infections. Meta-analyses of randomized controlled trials have yielded conflicting results, with some indicating modest reductions in infection incidence and duration, while others find no significant benefits. Variability in Echinacea species, plant parts utilized, extraction methods, dosing regimens, and study populations likely contribute to inconsistent findings. Studies employing standardized preparations and adequate sample sizes more consistently demonstrate benefits, suggesting that product quality and study design critically influence outcomes.

Clinical trials investigating Panax ginseng have focused on immunostimulation in elderly populations, enhancement of vaccine responses, and supportive care in cancer patients. Studies in older adults demonstrate that ginseng supplementation enhances various immune parameters including natural killer cell activity, T cell proliferation, and antibody production. A randomized controlled trial examining influenza vaccination in elderly subjects found that ginseng co-administration improved antibody titers and reduced infection rates compared to placebo. Cancer patients receiving ginseng during chemotherapy have reported improved quality of life and reduced infection rates in some studies, though effects on tumor outcomes remain uncertain. Standardization of ginsenoside content appears critical for consistent clinical effects.

Withania somnifera has been evaluated in clinical trials for stress reduction, anti-inflammatory effects, and cancer supportive care. Studies in patients with various inflammatory conditions demonstrate reductions in inflammatory markers including C-reactive protein and pro-inflammatory cytokines following Withania supplementation. Cancer patients receiving Withania extracts alongside conventional therapy report improvements in fatigue, quality of life, and immune parameters, though impacts on survival require further investigation. Adaptogenic effects of Withania, including stress reduction and improved resilience, may indirectly support immune function through modulation of hypothalamic-pituitaryadrenal axis activity and reduction of stress-induced immunosuppression.

Curcumin has been investigated extensively in clinical trials for inflammatory and autoimmune conditions, though bioavailability limitations have complicated interpretation of results and necessitated development of enhanced formulations. Studies in patients with rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease have demonstrated anti-inflammatory benefits and symptom improvement with curcumin supplementation. Formulations incorporating phospholipids, nanoparticles, or absorption enhancers demonstrate improved bioavailability and more consistent clinical effects. Cancer patients receiving curcumin have shown reductions in inflammatory markers and improvements in some quality of life parameters, though effects on tumor outcomes require further validation in larger trials.

Astragalus membranaceus has been evaluated primarily as supportive therapy in cancer patients and for prevention of respiratory infections. Clinical trials in cancer patients receiving chemotherapy demonstrate that Astragalus supplementation reduces treatment-related toxicity, improves immune parameters, and may enhance tumor responses in some contexts. Studies examining infection prevention indicate that regular Astragalus consumption reduces frequency of upper respiratory infections and may accelerate recovery. Traditional Chinese medicine practice commonly employs Astragalus in combination formulas, complicating attribution of effects to individual components. Standardization to polysaccharide content appears important for reproducible immunomodulatory effects.

Uncaria tomentosa has been investigated clinically primarily for osteoarthritis and rheumatoid arthritis, with trials demonstrating reduced pain and inflammation compared to placebo. Immunological assessments in trial participants reveal anti-inflammatory effects including reduced pro-inflammatory cytokine levels and decreased inflammatory cell activation. Small trials in cancer patients suggest potential immunostimulatory effects, though larger controlled studies are needed. The anti-inflammatory properties of Uncaria may benefit conditions involving excessive immune activation, while immunostimulatory effects could support antimicrobial defense.

Clinical trials of Andrographis paniculata have focused predominantly on upper respiratory tract infection treatment and prevention. Multiple randomized controlled trials and meta-analyses support efficacy in reducing symptom severity and duration of uncomplicated upper respiratory infections when initiated early in the course of illness. Proposed mechanisms include anti-inflammatory effects, enhancement of cellular immune responses, and potential direct antiviral activity. Safety profiles in clinical trials have been favorable, with minimal adverse effects reported. Combination products containing Andrographis with other herbs have also demonstrated benefits, though attribution of effects requires careful study design.

Challenges in clinical investigation of plant-derived immunomodulators include variability in botanical source material, lack of standardization, difficulties in blinding due to organoleptic properties, heterogeneity of patient populations, and limitations in funding for large-scale trials. Many studies have been conducted in specific geographic regions where traditional use is established, limiting generalizability. Outcome measures have varied considerably across studies, with some focusing on immunological parameters while others assess clinical endpoints. Longer-term studies examining chronic use, optimal dosing strategies, and potential synergies with conventional therapies represent important research priorities.

Formulation and Delivery Strategies

Effective therapeutic application of plant-derived immunomodulators requires optimization of formulation and delivery strategies to address challenges including variable phytochemical content, limited bioavailability, chemical instability, and need for standardization. Traditional preparation methods such as aqueous decoctions, ethanolic extracts, and powdered plant materials continue to be employed, but modern pharmaceutical approaches have enabled development of more sophisticated delivery systems. Standardization to marker compounds or bioactive constituents represents a fundamental requirement for reproducible therapeutic effects and enables quality control across production batches.

Extract preparation methodology significantly influences phytochemical composition and biological activity. Solvent selection, extraction temperature, duration, and solid-to-solvent ratio affect recovery of different compound classes. Aqueous extracts typically contain polysaccharides, glycosides, and hydrophilic phenolics, while ethanolic or hydroalcoholic extracts recover a broader spectrum including lipophilic compounds. Supercritical fluid extraction, ultrasound-assisted extraction, and microwave-assisted extraction represent advanced techniques that may enhance efficiency and selectivity. Sequential extraction using solvents of increasing polarity enables fractionation of compounds with different physicochemical properties. Comparison of extraction methods for identical plant materials reveals substantial variation in immunomodulatory activity, underscoring the importance of method optimization.

Bioavailability limitations represent a major obstacle to clinical translation of many immunoactive phytochemicals, particularly polyphenolic compounds such as curcumin. Factors contributing to poor bioavailability include limited aqueous solubility, chemical instability, extensive first-pass metabolism, and active efflux transport. Multiple strategies have been developed to address these challenges. Phospholipid complexes, or phytosomes, enhance absorption of lipophilic compounds by forming complexes with phosphatidylcholine that facilitate incorporation into biological membranes. Nanoparticle formulations including polymeric nanoparticles, solid lipid nanoparticles, and liposomes protect compounds from degradation, improve tissue distribution, and enable controlled release. Co-administration with absorption enhancers such as piperine inhibits metabolic enzymes and efflux transporters, increasing systemic exposure.

Targeted delivery strategies aim to enhance accumulation of immunomodulatory compounds at relevant immune tissues or cells. Conjugation of phytochemicals to targeting ligands that recognize specific cell surface receptors enables selective uptake by desired cell populations. Mannose or mannan conjugation facilitates macrophage and dendritic cell targeting through mannose receptor-mediated endocytosis. Particle size manipulation influences biodistribution, with nanoscale particles preferentially accumulating in lymphoid tissues through lymphatic drainage or phagocytic uptake.

Surface charge modification affects cellular interactions, with cationic formulations demonstrating enhanced cellular uptake but potential toxicity concerns. Stimuli-responsive delivery systems that release cargo in response to pH, enzymes, or inflammatory mediators enable site-specific drug release at sites of immune activation.

Sustained-release formulations extend duration of action and reduce dosing frequency, improving patient compliance and maintaining therapeutic concentrations. Matrix systems incorporating phytochemicals within hydrophilic or lipophilic polymer matrices provide controlled release through diffusion and polymer erosion mechanisms. Microencapsulation protects sensitive compounds from environmental degradation while enabling timed release. Transdermal delivery systems avoid first-pass metabolism and provide sustained systemic exposure, though penetration of large or hydrophilic molecules remains challenging. Mucoadhesive formulations for oral, nasal, or sublingual administration prolong residence time at absorption sites, enhancing bioavailability.

Combination formulations containing multiple botanicals or purified compounds represent a common approach in traditional medicine systems and may offer advantages through synergistic interactions. Pharmacokinetic synergy occurs when one compound enhances absorption, reduces metabolism, or inhibits efflux of another. Pharmacodynamic synergy involves complementary actions on different molecular targets within common pathways or additive effects on multiple pathways contributing to therapeutic outcomes. Systematic investigation of combination effects requires factorial experimental designs and appropriate statistical analysis to distinguish synergy from additive effects. Some traditional formulations demonstrating clinical efficacy contain complex mixtures whose individual components show limited activity, suggesting that multi-component interactions contribute to overall effects [85, 86].

Quality control and standardization procedures ensure consistency of phytochemical content and biological activity across production batches. Analytical methods including high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance spectroscopy enable quantification of marker compounds and chemical fingerprinting. Biological standardization through *in vitro* immunoassays ensures functional consistency even when chemical composition varies due to natural variability in plant materials. Good manufacturing practices, quality assurance protocols, and stability testing represent essential components of pharmaceutical development for plant-derived products. Authentication of botanical identity through macroscopic, microscopic, and molecular methods prevents adulteration and substitution.

Safety, Toxicity, and Herb–Drug Interactions

Evaluation of safety and toxicity represents a critical component of clinical development for plant-derived immunomodulators, despite common perceptions that natural products are inherently safe. Acute toxicity studies in animal models have generally demonstrated wide safety margins for most traditional immunomodulatory plants at recommended therapeutic doses. However, high doses or prolonged administration may elicit adverse effects. Chronic toxicity studies of Panax ginseng reveal potential for insomnia, hypertension, and nervous system stimulation at excessive doses. Glycyrrhiza glabra consumption, particularly at high doses or with extended duration, causes mineralocorticoid effects including hypertension, hypokalemia, and fluid retention due to glycyrrhizin inhibition of 11-beta-hydroxysteroid dehydrogenase.

Immunological safety concerns include potential for excessive immunostimulation in individuals with autoimmune diseases or predisposition to such conditions. Theoretical risks exist that immunostimulatory botanicals could exacerbate autoimmune pathology by enhancing autoreactive immune responses. Clinical evidence for such effects remains limited, but caution is warranted in patients with conditions such as multiple sclerosis, systemic lupus erythematosus, or rheumatoid arthritis. Conversely, immunosuppressive botanicals could theoretically increase infection risk or compromise vaccine responses, though clinical data supporting these concerns are sparse. Individual variability in immune status, genetic polymorphisms affecting drug metabolism, and baseline disease activity likely influence susceptibility to immunological adverse effects.

Allergic reactions to medicinal plants occur with variable frequency depending on species and individual sensitization. Echinacea, a member of the Asteraceae family, may trigger allergic responses in individuals with sensitivities to related plants including ragweed, chrysanthemums, and marigolds. Manifestations range from mild dermatological reactions to severe anaphylaxis in rare cases. Cross-reactivity between botanicals and environmental allergens represents an under-recognized concern. Thorough patient history regarding allergies to plants, pollens, and foods assists in identifying individuals at increased risk. Gradual dose escalation and monitoring for allergic symptoms during initial administration can mitigate risks.

Herb-drug interactions constitute significant safety concerns, particularly for individuals receiving conventional immunosuppressive or immunomodulatory therapies. Pharmacokinetic interactions occur when botanicals alter absorption, distribution, metabolism, or elimination of co-administered drugs. Many phytochemicals modulate cytochrome P450 enzyme activity, with potential for clinically significant interactions. St. John's wort induces CYP3A4 and reduces exposure to numerous medications including immunosuppressants such as cyclosporine and tacrolimus, potentially precipitating transplant rejection. Grapefruit juice inhibits CYP3A4 and increases blood levels of drugs metabolized by this pathway. Garlic, ginseng, and ginkgo have been implicated in interactions with anticoagulants, increasing bleeding risk.

Pharmacodynamic interactions involve additive, synergistic, or antagonistic effects on shared therapeutic targets or physiological systems. Concurrent use of immunostimulatory botanicals with immunosuppressive drugs could theoretically reduce efficacy of immunosuppression, though clinical evidence remains limited. Conversely, combining immunosuppressive botanicals with immunosuppressive medications may increase risk of opportunistic infections. Interactions with cancer immunotherapies represent an emerging concern, as some botanicals might interfere with checkpoint inhibitor mechanisms or modify tumor microenvironment in unpredictable ways. Systematic evaluation of potential interactions through clinical trials and pharmacovigilance programs remains insufficient.

Contamination and adulteration of botanical products represent serious safety concerns that have led to adverse events. Heavy metal contamination from soil or processing equipment poses toxicity risks, particularly with products sourced from regions with inadequate environmental regulations. Microbial contamination with bacteria, fungi, or their toxins can occur during cultivation, processing, or storage. Adulteration with undeclared pharmaceutical agents, particularly in products marketed for specific conditions, has been documented and may cause unexpected adverse effects. Misidentification or substitution of plant species, whether intentional or inadvertent, can result in consumption of toxic plants. Rigorous quality control, third-party testing, and regulatory oversight are essential safeguards.

Specific populations require particular safety considerations. Pregnancy and lactation represent periods when immunomodulatory effects could theoretically impact fetal development or infant health, though data are extremely limited for most botanicals. Many traditional systems contraindicate certain immunostimulatory herbs during pregnancy based on theoretical concerns or historical observations. Pediatric use necessitates consideration of developmental differences in immune function, drug metabolism, and safety margins. Elderly individuals may exhibit altered pharmacokinetics, increased susceptibility to adverse effects, and higher likelihood of polypharmacy with attendant interaction risks. Individuals with hepatic or renal impairment require dose adjustment considerations for botanicals eliminated through these routes.

Regulatory and Standardization Challenges

Regulatory frameworks governing development, marketing, and use of plant-derived immunomodulators vary substantially across jurisdictions, creating challenges for international development and commercialization. In the United States, botanical products are primarily regulated as dietary supplements under the Dietary Supplement Health and Education Act, which permits marketing without premarket approval provided structure-function claims do not imply treatment or prevention of diseases. This regulatory pathway imposes less stringent requirements for safety and efficacy data compared to pharmaceutical drugs, though manufacturers remain responsible for product safety and must substantiate claims. The botanical drug approval pathway, exemplified by approval of veregen for genital warts, requires comprehensive quality control, safety testing, and efficacy demonstration through clinical trials similar to synthetic drugs.

European Union regulations classify herbal medicinal products under Directive 2001/83/EC, requiring marketing authorization based on well-established use or traditional use registration. Well-established use registration demands bibliographic evidence of safety and efficacy with at least ten years of medicinal use in the European Union, while traditional use registration requires at least thirty years of use including fifteen years within the European Union. The European Medicines Agency maintains monographs through the Committee on Herbal Medicinal Products providing detailed specifications for quality, safety, and efficacy of commonly used herbs. This system provides more structured oversight than dietary supplement regulations while accommodating traditional use evidence.

Traditional medicine systems in countries such as India, China, and Japan have established regulatory frameworks specific to traditional preparations. The Ayurvedic, Siddha, and Unani Drugs Technical Advisory Board in India oversees traditional medicine products, while China's National Medical Products Administration regulates traditional Chinese medicines. These systems often permit marketing of traditional formulations based on historical use documentation without requiring modern clinical trial evidence, though new products or novel indications typically require safety and efficacy data. Efforts to harmonize traditional medicine regulations through international cooperation remain ongoing but face challenges due to fundamental differences in evidence requirements and philosophical approaches.

Standardization of botanical products presents technical challenges due to inherent variability in plant materials influenced by genetics, growing conditions, harvest timing, processing methods, and storage. Multiple approaches to standardization exist, each with advantages and limitations. Marker compound standardization quantifies one or more characteristic constituents to specified ranges, enabling consistency across batches. However, marker compounds may not represent the full spectrum of bioactive constituents or correlate perfectly with biological activity. Bioassay-guided standardization uses functional assays to ensure consistent biological activity, though such assays may be labor-intensive and variable. Chemical fingerprinting using chromatographic or spectroscopic methods characterizes the complete chemical profile, enabling detection of variations and adulterations while preserving complexity.

Quality control procedures for botanical immunomodulators must address multiple parameters including botanical authentication, phytochemical quantification, contaminant screening, microbiological testing, and stability assessment. Botanical authentication employs macroscopic and microscopic morphological examination, chemical fingerprinting, and increasingly DNA barcoding to confirm species identity and detect substitutions. Quantitative analysis of marker compounds using validated analytical methods ensures content meets specifications. Testing for heavy metals, pesticide residues, mycotoxins, and microbial contamination protects against safety hazards. Stability studies under defined storage conditions establish shelf life and inform packaging and storage requirements.

Good agricultural and collection practices for medicinal plants address quality from cultivation through harvesting and initial processing. These practices specify appropriate growing conditions, pest management approaches, harvest timing, post-harvest handling, and traceability systems. Sustainable sourcing considerations become increasingly important as demand for medicinal plants grows and some species face overexploitation. Cultivation under controlled conditions offers advantages for quality consistency and sustainability compared to wild harvesting, though requirements for land, water, and agricultural inputs create environmental considerations. Certification programs for organic cultivation and fair-trade practices address consumer preferences and ethical sourcing.

Intellectual property considerations complicate development of traditional plant-based medicines, particularly regarding traditional knowledge held by indigenous communities. The Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization addresses access to genetic resources and associated traditional knowledge, requiring prior informed consent and benefit-sharing arrangements. Pharmaceutical companies developing products from traditional medicines must navigate these legal frameworks while indigenous communities seek recognition and compensation for traditional knowledge contributions. Patent systems in different jurisdictions vary in approaches to protecting innovations related to traditional knowledge, with some permitting broad claims and others requiring novelty beyond traditional use.

Future Directions in Plant-Derived Immunomodulatory Drug Development

Advancement of plant-derived immunomodulators from traditional use and preclinical investigation toward evidence-based therapeutics requires strategic research investments addressing current knowledge gaps and methodological limitations. High-priority areas include comprehensive phytochemical characterization using advanced analytical platforms, elucidation of molecular mechanisms through systems biology approaches, optimization of formulations for enhanced bioavailability and targeted delivery, conduct of rigorous clinical trials with appropriate design and endpoints, and development of rational combination strategies integrating botanical and conventional therapies. Emerging technologies in genomics, proteomics, metabolomics, and bioinformatics offer unprecedented opportunities for understanding complex plant-immune system interactions and identifying novel therapeutic candidates.

Genomic and transcriptomic approaches enable comprehensive characterization of immune system responses to botanical interventions at unprecedented resolution. RNA sequencing analysis of immune cells exposed to phytochemicals reveals global gene expression changes, identifying regulated pathways and potential biomarkers of response. Single-cell RNA sequencing permits examination of heterogeneous immune cell populations, revealing cell type-specific effects masked in bulk analyses. Comparative transcriptomics across multiple botanicals or phytochemicals identifies common and unique mechanisms, informing structure-activity relationships and combination strategies. Integration of transcriptomic data with clinical outcomes may identify predictive signatures for therapeutic response and guide patient selection.

Metabolomics and proteomics provide complementary insights into functional consequences of immune modulation by plant-derived compounds. Mass spectrometry-based metabolomics characterizes small molecule metabolites reflecting cellular metabolic states influenced by immunomodulatory interventions. Shifts in energy metabolism, lipid profiles, and amino acid metabolism correlate with immune cell activation states and functional capacities. Proteomics quantifies protein expression and post-translational modifications, revealing changes in signaling molecules, transcription factors, and effector proteins. Phosphoproteomics specifically examines signaling pathway activation through phosphorylation events. Integration of multi-omics datasets through systems biology approaches constructs network models of plant-immune interactions, identifying hub proteins and pathways as potential therapeutic targets.

Artificial intelligence and machine learning applications accelerate discovery and optimization of immunomodulatory natural products. Quantitative structure-activity relationship models predict immunological activities from chemical structures, enabling virtual screening of compound libraries and prioritization of candidates for experimental validation. Machine learning algorithms trained on existing datasets identify patterns correlating botanical source, phytochemical composition, extraction methods, and biological activities, informing optimization strategies. Natural language processing of traditional medicine literature and scientific publications extracts knowledge regarding plant uses, combinations, and preparation methods, identifying underexplored candidates. Network pharmacology approaches map complex interactions between multiple compounds, targets, and pathways, providing mechanistic insights into multi-component formulations.

Precision medicine approaches tailoring immunomodulatory interventions to individual patient characteristics represent an important future direction. Genetic polymorphisms affecting immune function, drug metabolism, and disease susceptibility influence responses to immunomodulatory therapies. Pharmacogenomic assessment of variants in cytochrome P450 enzymes, drug transporters, and immune receptors could guide dose selection and predict adverse effects. Immune profiling characterizing baseline immune status through comprehensive assessment of cell populations, cytokine levels, and functional capacities may identify individuals most likely to benefit from immunostimulatory versus immunosuppressive interventions. Microbiome analysis reveals gut microbial composition, which influences immune function and metabolism of plant-derived compounds, potentially informing treatment selection.

Rational combination strategies integrating plant-derived immunomodulators with conventional therapies offer potential for enhanced efficacy and reduced toxicity. Preclinical studies demonstrating synergistic interactions between botanicals and chemotherapy, radiation, or immunotherapy warrant clinical translation. Mechanisms of synergy include complementary actions on tumor cells and immune components, reversal of immunosuppressive tumor microenvironment, enhancement of antigen presentation, and reduction of treatment-related immunotoxicity. Optimal sequencing, dosing, and duration of combination regimens require systematic investigation. Adaptive clinical trial designs enable efficient evaluation of multiple combinations and identification of promising regimens for definitive testing.

Development of next-generation formulations leveraging nanotechnology, biomaterials, and targeted delivery continues to address bioavailability and specificity limitations. Nanocarrier systems incorporating multiple immunomodulatory compounds enable synchronized delivery and synergistic interactions at target sites. Stimuli-responsive delivery systems releasing cargo in response to inflammatory signals or other disease-associated triggers provide spatiotemporal control. Biomimetic delivery platforms utilizing cell membrane-coated nanoparticles evade immune clearance while targeting specific tissues. Injectable hydrogels containing immunomodulatory botanicals provide sustained local release for applications such as wound healing or cancer immunotherapy. Thorough safety evaluation of novel delivery systems remains essential given potential toxicity of nanomaterials.

Conclusion

Medicinal plants represent a rich and largely underexplored source of immunomodulatory agents with potential for addressing unmet clinical needs in infectious diseases, autoimmune disorders, chronic inflammation, and cancer.

Centuries of traditional use across diverse cultures provide valuable insights into therapeutic applications, though rigorous scientific validation remains essential for evidence-based integration into modern healthcare systems. Extensive preclinical investigations have identified numerous plants and isolated phytochemicals with capacity to modulate innate and adaptive immune responses through diverse molecular mechanisms including pattern recognition receptor activation, transcription factor modulation, cytokine network regulation, and immune cell functional enhancement or suppression. Polysaccharides, alkaloids, terpenoids, flavonoids, and other phytochemical classes demonstrate immunological activities that may complement or provide alternatives to synthetic immunomodulatory drugs.

Clinical evidence supporting therapeutic applications of plant-derived immunomodulators has grown substantially but remains limited by methodological constraints including small sample sizes, lack of standardization, heterogeneous outcome measures, and inadequate mechanistic investigation. Meta-analyses of clinical trials for botanicals such as Echinacea, ginseng, and Andrographis suggest modest benefits for specific indications, though larger and more rigorous studies are needed to establish definitive efficacy and optimal utilization strategies. Variability in botanical source material, extraction methods, formulations, and dosing regimens complicate interpretation of clinical data and highlights the critical importance of product standardization and quality control. Enhanced bioavailability formulations and targeted delivery systems offer promise for improving therapeutic efficacy while minimizing off-target effects.

Safety considerations encompass potential for allergic reactions, excessive immunostimulation in susceptible individuals, herb-drug interactions affecting conventional therapies, and contamination or adulteration of botanical products. While many traditional immunomodulatory plants demonstrate favorable safety profiles at recommended doses, individual variability and special populations require careful consideration. Herb-drug interaction potential, particularly with immunosuppressants, chemotherapy, and anticoagulants, necessitates vigilant monitoring and communication between patients and healthcare providers. Regulatory frameworks governing botanical products vary widely across jurisdictions, creating challenges for standardization, quality assurance, and international development. Harmonization of regulatory approaches while respecting traditional knowledge and use patterns represents an ongoing challenge requiring multistakeholder collaboration.

Future advancement of plant-derived immunomodulators toward mainstream therapeutic applications requires strategic research investments in multiple domains. Comprehensive chemical and biological characterization using advanced analytical platforms, multi-omics technologies, and systems biology approaches will elucidate complex mechanisms and identify optimal therapeutic applications. Rigorous clinical trials employing appropriate designs, standardized products, and mechanistic endpoints are essential for establishing efficacy and safety. Development of precision medicine approaches incorporating genetic, immunological, and microbiome profiling may enable individualized therapy selection. Rational combinations with conventional therapies warrant systematic investigation given preclinical evidence of synergistic interactions. Next-generation formulations addressing bioavailability and targeted delivery limitations will enhance therapeutic potential. Ultimately, successful translation of plant-derived immunomodulators into evidence-based therapies requires integration of traditional knowledge, modern scientific methodologies, pharmaceutical innovation, and regulatory frameworks that ensure quality, safety, and efficacy while respecting intellectual property and benefit-sharing considerations.

References

1. Schett G, Neurath MF. Resolution of chronic inflammatory disease: universal and tissue-specific concepts. Nat Commun. 2018;9(1):3261.
2. Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020;12(3):738.
3. Wachtel-Galor S, Benzie IFF. Herbal medicine: an introduction to its history, usage, regulation, current trends, and research needs. In: Benzie IFF, Wachtel-Galor S, editors. Herbal medicine: biomolecular and clinical aspects. 2nd ed. Boca Raton: CRC Press; 2011. p. 1.
4. Patwardhan B, Warude D, Pushpangadan P, Bhatt N. Ayurveda and traditional Chinese medicine: a comparative overview. Evid Based Complement Alternat Med. 2005;2(4):465-73.
5. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770-803.
6. Wagner H, Ulrich-Merzenich G. Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine. 2009;16(2-3):97-110.
7. Medzhitov R, Janeway CA Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell. 1997;91(3):295-8.
8. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805-20.
9. Bonilla FA, Oettgen HC. Adaptive immunity. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S33-40.
10. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245-52.
11. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B in inflammatory bowel disease. Gut. 1998;42(4):477-84.
12. Espinosa A, Dardalhon V, Brauner S, Ambrosi A, Higgs R, Quintana FJ, *et al*. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med. 2009;206(8):1661-71.
13. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002;20:197-216.
14. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011;474(7351):298-306.
15. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 1996;17(3):138-46.
16. Davis MM, Tato CM, Furman D. Systems immunology: just getting started. Nat Immunol. 2017;18(7):725-32.
17. Barrett B. Medicinal properties of Echinacea: a critical review. Phytomedicine. 2003;10(1):66-86.
18. Sharma M, Arnason JT, Burt A, Hudson JB. Echinacea extracts modulate the pattern of chemokine and cytokine

secretion in rhinovirus-infected and uninfected epithelial cells. Phytother Res. 2006;20(2):147-52.
19. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev. 2000;5(4):334-46.
20. Malik F, Singh J, Khajuria A, Suri KA, Satti NK, Singh S, *et al*. A standardized root extract of Withania somnifera and its major constituent withanolide-A elicit humoral and cell-mediated immune responses by up regulation of Th1-dominant polarization in BALB/c mice. Life Sci. 2007;80(16):1525-38.
21. Kang S, Min H. Ginseng, the 'immunity boost': the effects of Panax ginseng on immune system. J Ginseng Res. 2012;36(4):354-68.
22. Seely D, Singh R, Sason A. An ethnopharmacological review of wild harvested and cultivated plants as treatments for prostate cancer. Fitoterapia. 2008;79(4):259-73.
23. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of turmeric (Curcuma longa). J Altern Complement Med. 2003;9(1):161-8.
24. Jagetia GC, Aggarwal BB. "Spicing up" of the immune system by curcumin. J Clin Immunol. 2007;27(1):19-35.
25. Auyeung KK, Han QB, Ko JK. Astragalus membranaceus: a review of its protection against inflammation and gastrointestinal cancers. Am J Chin Med. 2016;44(1):1-22.
26. Block KI, Mead MN. Immune system effects of Echinacea, ginseng, and astragalus: a review. Integr Cancer Ther. 2003;2(3):247-67.
27. Heitzman ME, Neto CC, Winiarz E, Vaisberg AJ, Hammond GB. Ethnobotany, phytochemistry and pharmacology of Uncaria (Rubiaceae). Phytochemistry. 2005;66(1):5-29.
28. Saxena RC, Singh R, Kumar P, Yadav SC, Negi MP, Saxena VS, *et al*. A randomized double blind placebo controlled clinical evaluation of extract of Andrographis paniculata (KalmCold) in patients with uncomplicated upper respiratory tract infection. Phytomedicine. 2010;17(3-4):178-85.
29. Fiore C, Eisenhut M, Krausse R, Ragazzi E, Pellati D, Armanini D, *et al*. Antiviral effects of Glycyrrhiza species. Phytother Res. 2008;22(2):141-8.
30. Upadhyay AK, Kumar K, Kumar A, Mishra HS. Tinospora cordifolia (Willd.) Hook. f. and Thoms. (Guduchi) – validation of the Ayurvedic pharmacology through experimental and clinical studies. Int J Ayurveda Res. 2010;1(2):112-21.
31. Schepetkin IA, Quinn MT. Botanical polysaccharides: macrophage immunomodulation and therapeutic potential. Int Immunopharmacol. 2006;6(3):317-33.
32. Yin M, Zhang Y, Li H. Advances in research on immunoregulation of macrophages by plant polysaccharides. Front Immunol. 2019;10:145.
33. Grover A, Katiyar SP, Jeyakanthan J, Dubey VK, Sundar D. Blocking protein kinase C signaling pathway: mechanistic insights into the anti-leishmanial activity of prospective herbal drugs from Withania somnifera. BMC Genomics. 2012;13 Suppl 7:S20.
34. Yeung KS, Gubili J, Mao JJ. Herb-drug interactions in cancer care. Oncology (Williston Park). 2018;32(10):516-20.
35. Kim KH, Lee YS, Jung IS, Park SY, Chung HY, Lee IR, *et al*. Acidic polysaccharide from Panax ginseng, ginsan, induces Th1 cell and macrophage cytokines and generates LAK cells in synergy with rIL-2. Planta Med. 1998;64(2):110-5.
36. Manu KA, Kuttan G. Immunomodulatory activities of a novel polysaccharide from Tinospora cordifolia. Int Immunopharmacol. 2009;9(13-14):1528-32.
37. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J. 2013;15(1):195-218.
38. Li Y, Yao J, Han C, Yang J, Chaudhry MT, Wang S, *et al*. Quercetin, inflammation and immunity. Nutrients. 2016;8(3):167.
39. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1(6):a001651.
40. Koeberle A, Werz O. Multi-target approach for natural products in inflammation. Drug Discov Today. 2014;19(12):1871-82.
41. Aggarwal S, Gollapudi S, Gupta S. Increased TNF-alpha-induced apoptosis in lymphocytes from aged humans: changes in TNF-alpha receptor expression and activation of caspases. J Immunol. 1999;162(4):2154-61.
42. Pan MH, Lai CS, Ho CT. Anti-inflammatory activity of natural dietary flavonoids. Food Funct. 2010;1(1):15-31.
43. Goel V, Lovlin R, Barton R, Lyon MR, Bauer R, Lee TD, *et al*. Efficacy of a standardized echinacea preparation (Echinilin) for the treatment of the common cold: a randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther. 2004;29(1):75-83.
44. Burger RA, Torres AR, Warren RP, Caldwell VD, Hughes BG. Echinacea-induced cytokine production by human macrophages. Int J Immunopharmacol. 1997;19(7):371-9.
45. Davis L, Kuttan G. Immunomodulatory activity of Withania somnifera. J Ethnopharmacol. 2000;71(1-2):193-200.
46. Rasool M, Varalakshmi P. Immunomodulatory role of Withania somnifera root powder on experimental induced inflammation: An *in vivo* and *in vitro* study. Vascul Pharmacol. 2006;44(6):406-10.
47. Shao BM, Xu W, Dai H, Tu P, Li Z, Gao XM. A study on the immune receptors for polysaccharides from the roots of Astragalus membranaceus, a Chinese medicinal herb. Biochem Biophys Res Commun. 2004;320(4):1103-11.
48. Cho WC, Leung KN. *In vitro* and *in vivo* immunomodulating and immunorestorative effects of Astragalus membranaceus. J Ethnopharmacol. 2007;113(1):132-41.
49. Shin JY, Song JY, Yun YS, Yang HO, Rhee DK, Pyo S. Immunostimulating effects of acidic polysaccharides extract of Panax ginseng on macrophage function. Immunopharmacol Immunotoxicol. 2002;24(3):469-82.
50. Scaglione F, Ferrara F, Dugnani S, Falchi M, Santoro G, Fraschini F. Immunomodulatory effects of two extracts of Panax ginseng C.A. Meyer. Drugs Exp Clin Res. 1990;16(10):537-42.
51. McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, *et al*. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-

cell lung cancer: meta-analysis of randomized trials. J Clin Oncol. 2006;24(3):419-30.
52. Currier NL, Miller SC. Echinacea purpurea and melatonin augment natural-killer cells in leukemic mice and prolong life span. J Altern Complement Med. 2001;7(3):241-51.
53. Funk JL, Frye JB, Oyarzo JN, Chen J, Zhang H, Timmermann BN. Anti-inflammatory effects of the essential oils of ginger (Zingiber officinale Roscoe) in experimental rheumatoid arthritis. PharmaNutrition. 2016;4(3):123-31.
54. Yao J, Zhang B, Ge C, Peng S, Fang J. Xanthohumol, a polyphenol chalcone present in hops, activating Nrf2 enzymes to confer protection against oxidative damage in PC12 cells. J Agric Food Chem. 2015;63(5):1521-31.